Parabilis Medicines, Inc. Common Stock (PBLS) - Net Assets
Based on the latest financial reports, Parabilis Medicines, Inc. Common Stock (PBLS) has net assets worth $244.22 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($384.17 Million) and total liabilities ($139.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Parabilis Medicines, Inc. Common Stock for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $244.22 Million |
| % of Total Assets | 63.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Parabilis Medicines, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Parabilis Medicines, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Check PBLS tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Parabilis Medicines, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Parabilis Medicines, Inc. Common Stock from 2024 to 2025. For live valuation and market cap data, see PBLS stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-16.52 Million | -129.28% |
| 2024-12-31 | $56.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Parabilis Medicines, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14588900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $524.98 Million | % |
| Total Equity | $-16.52 Million | 100.00% |
Parabilis Medicines, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Parabilis Medicines, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IGO Ltd
AU:IGO
|
$3.69 Billion |
|
Cleanaway Waste Management Ltd
AU:CWY
|
$3.69 Billion |
|
Hiwin Technologies Corp
TW:2049
|
$3.70 Billion |
|
MANDARIN ORIENTAL DL-05
F:1C4
|
$3.70 Billion |
|
Shanghai Xinmei Real Estate Co Ltd Class A
SHG:600732
|
$3.69 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
$3.69 Billion |
|
WPP PLC ADR
F:0WPA
|
$3.69 Billion |
|
Downer Edi Ltd
AU:DOW
|
$3.69 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Parabilis Medicines, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 56,439,000 to -16,524,000, a change of -72,963,000 (-129.3%).
- Net loss of 145,889,000 reduced equity.
- Share repurchases of 62,000 reduced equity.
- New share issuances of 67,491,000 increased equity.
- Other factors increased equity by 5,497,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-145.89 Million | -882.89% |
| Share Repurchases | $62.00K | -0.38% |
| Share Issuances | $67.49 Million | +408.44% |
| Other Changes | $5.50 Million | +33.27% |
| Total Change | $- | -129.28% |
Book Value vs Market Value Analysis
This analysis compares Parabilis Medicines, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $0.48 | $30.57 | x |
| 2025-12-31 | $-0.14 | $30.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Parabilis Medicines, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-104.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | -208.92% | 0.00% | 0.00x | 2.64x | $-123.56 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-144.24 Million |
Industry Comparison
This section compares Parabilis Medicines, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $147,081,944
- Average return on equity (ROE) among peers: -21.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Parabilis Medicines, Inc. Common Stock (PBLS) | $244.22 Million | -208.92% | 0.57x | $3.69 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $165.48 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $39.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $12.08 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.66 Billion |
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein … Read more